title: [Changes in the lipid profile in children with acute lymphoblastic leukaemia - the influence of the disease and its treatment].
abstract: The aim of the study was a prospective evaluation of the lipid profile in children with acute lymphoblastic leukaemia, before and during the treatment with L-asparaginase.
  
  
  METHODS
  Twenty-four children treated according to the ALLIC 2002 protocol entered the study. Blood samples were collected during the induction phase of treatment, on the 1st, 21st and 30(33)th day. The concentration of the total cholesterol, HDL and LDL cholesterol and triglycerides was determined. The results were analyzed in relation to the Body Mass Index, the WBC count and L-asparaginase activity. At the moment of diagnosis significantly low concentration of total cholesterol (124 mg/dl (103-153) vs 161 mg/dl (143-185), p=0,011) and HDL cholesterol (23 mg/dl (17-27) vs 56 mg/dl (44-64), p=0,00001) were observed, as well as high concentration of triglycerides (112 mg/dl (83-162) vs 73 mg/dl (62-99), p=0,009). The concentration of LDL cholesterol was similar to that observed in the control group. During further treatment the increase of the total cholesterol concentration was observed, but it was still significantly lower, when compared with the control. The values of triglycerides were significantly higher then those observed in healthy children (day 21: 88 mg/dl (67-170), p=0.08, day 33: 111 mg/dl (96-104) p=0.0004). The concentration of HDL cholesterol has increased during the treatment, but it was still lower than the HDL concentration in the control group (day 38: mg/dl (29-53), day 33: 30 mg/dl (16-50), p=0.009). No association between lipid concentration and BMI, WBC and L-asparaginase activity were found.
  
  
  CONCLUSIONS
  At the moment of diagnosis of ALL the potentially atherogenic lipid profile could be established. This tendency subsists during the induction phase, regardless of slight differences in particular lipid fractions.
authors.affiliation: Klinika Pediatrii, Onkologii, Hematologii i Diabetologii I Katedry Pediatrii, Uniwersytet Medyczny w łodzi, ul. Sporna 36/50, 91-718 łódź, Poland. bszewczy@toya.net.pl
authors.forename: Beata
authors.initials: B
authors.lastname: Zalewska-Szewczyk
authors.forename: Iwona
authors.initials: I
authors.lastname: Matusiak
authors.forename: Krystyna
authors.initials: K
authors.lastname: Wyka
authors.forename: Joanna
authors.initials: J
authors.lastname: Trelińska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Stolarska
authors.forename: Wojciech
authors.initials: W
authors.lastname: Młynarski
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001215:Asparaginase / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000378:metabolism*; D011446:Prospective Studies; D014280:Triglycerides / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D002784:Cholesterol; D001215:Asparaginase